Skip to main content
SpringerLink
Log in

Comparison of transforming growth factor β and a human tumour-derived suppressor factor

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Serum-free supernatants from the human melanoma cell line G361 contain a factor that can potently suppress the generation of tumouricidal lymphokine-activated killer (LAK) cells in response to interleukin-2. To characterise the suppressive factor of tumour origin we performed a number of physicochemical and functional comparisons with another immunosuppressive protein, transforming growth factor β (TGFβ). The bioactivity of tumour-derived suppressor factor (TDSF), assayed by suppression of LAK cell generation, was unaffected by a reducing agent but lost when denatured with a chaotropic agent. In contrast, TGFβ was inactivated by reduction but not denaturation. TDSF lost bioactivity in conditions of pH less than 4, whereas TGFβ showed no loss of activity. The TDSF moiety has an estimated pI of 4.3 and a molecular mass of 69–87 kDa. This differs from published values of pI 9.5, and 25 kDa molecular mass for TGFβ. Anti-TGFβ antiserum reversed the effects of TGFβ but did not affect the suppression of LAK cell generation caused by TDSF. These findings provide compelling evidence that the TDSF moiety is not TGFβ, and may be a novel immunoregulatory cytokine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anzano MA, Rieman D, Pritchett W, Bowen-Pope DF, Greig R (1989) Growth factor production by human colon carcinoma cell lines. Cancer Res 49: 2898

    PubMed  Google Scholar 

  2. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB (1983) Transforming growth factor-beta in human platelets; identification of a major storage site, purification and characterization. J Biol Chem 258: 7155

    PubMed  Google Scholar 

  3. Childs CB, Proper JA, Tucker RF, Moses HL (1982), Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 79: 5312

    PubMed  Google Scholar 

  4. DeFries RU, Golub SH (1988) Characteristics and mechanism of IFN-gamma induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol 140: 3686

    PubMed  Google Scholar 

  5. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL and Chen EY (1988) A new type of transforming growth factor-β, TGFβ3. EMBO J 7: 3737

    PubMed  Google Scholar 

  6. Dye JF, Somers SS, Guillou PJ (1991) Quantification of cytotoxicity by integration of specific lysis against effector cell concentration at constant target cell concentration: area under curve. J Immunol Methods (in press)

  7. Ebert EC, Roberts AI, O'Connell SM, Robertson FM, Nagase H (1987) Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 138: 2161

    PubMed  Google Scholar 

  8. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schlaub LB (1988) TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 27: 53

    PubMed  Google Scholar 

  9. Guillou PJ, Sedman PC, Ramsden CW (1989a) Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother 28: 43

    PubMed  Google Scholar 

  10. Guillou PJ, Ramsden CW, Somers SS, Sedman PC (1989b) Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumor cell lines. Br J Cancer 59: 515

    PubMed  Google Scholar 

  11. Kehrl JH, Wakefield LM, Roberts AB, Jakowlel S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS (1986), The production of TGF-beta by human T-Lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 163: 1037

    PubMed  Google Scholar 

  12. Kehrl JH, Taylor AS, Delsing GS, Roberts AB, Sporn MB, Fauci AS (1989) Further studies of the role of transforming growth factor-beta in human B-cell function. J Immunol 143: 1868

    PubMed  Google Scholar 

  13. Kuppner MC, Hamou MF, Bodmer S, Fontana A, De Tribolet N (1988) The glioblastoma-derived T-cell suppressor factor/transforming growth factor-beta2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42: 562

    PubMed  Google Scholar 

  14. Lyons RM, Keski-Oja J, Moses HL (1988) Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium. J Cell Biol 106: 1659

    PubMed  Google Scholar 

  15. Monson JRT, Ramsden CW, Guillou PJ (1986) Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 73: 483

    PubMed  Google Scholar 

  16. Monson JRT, Ramsden CW, Giles GR, Brennan TG, Guillou PJ (1987) Lymphokine-activated killer (LAK) cells in patients with gastrointestinal cancer. Gut 28: 1420

    PubMed  Google Scholar 

  17. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95

    PubMed  Google Scholar 

  18. Remacle-Bonnet MM, Pommier GJ, Kaplanski S, Rance RJ, Depieds RC (1976) Inhibition of normal allogenic lymphocyte mitogenesis by a soluble inhibitor extracted from human colonic carcinoma. J Immunol 117: 1145

    PubMed  Google Scholar 

  19. Roberts AB, Frolik CA, Anzano MA, Sporn MB (1983) Transforming growth factors from neoplastic and non-neoplastic tissues. Fed Proc 42: 2621

    PubMed  Google Scholar 

  20. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Bulington DB, Lane C, Fauci AS (1986) Effects of transforming growth factor-beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916

    PubMed  Google Scholar 

  21. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Marston Linehan W, Seipp C, White DE (1989) Experience in the use of high-dose Interleukin-2 in the treatment of 652 cancer patients. Ann Surg 201: 474

    Google Scholar 

  22. Roth JA, Grimm EA, Gupta RK, Ames RS (1982) Immunoregulatory factors derived from human tumors: 1. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J Immunol 128: 1955

    PubMed  Google Scholar 

  23. Roth JA, Osborne BA, Ames RS (1983) Immunoregulatory factors derived from human tumors: 2. partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin determinants. J Immunol 130: 303

    PubMed  Google Scholar 

  24. Seyedin SM, Segarini PR, Rosen DM, Thompson AY, Bentz H, Graycar J (1987) Cartilage inducing factor-B is a unique protein structurally and functionally related to transforming growth factor-β. J Biol Chem 262: 1946

    PubMed  Google Scholar 

  25. Shiiba K, Suzuki R, Kawakami K, Ohuchi A, Kumagi K (1986) Interleukin-2 activated killer cells: generation in collaboration with interferon-gamma and its suppression in cancer patients. Cancer Immunol Immunother 21: 119

    PubMed  Google Scholar 

  26. Sporn MB, Roberts AB, Wakefield LM, Assoian RK (1986) Transforming growth factor-β: biologic function and chemical structure. Science 233: 532

    PubMed  Google Scholar 

  27. Torre-Amione G, Beachamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type-β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87: 1486

    PubMed  Google Scholar 

  28. Werkmeister J, Zbroja R, McCarthy W, Hersey P (1980) Detection of an inhibitor of cell division in cultures of tumor cells with immunosuppressive activity in vitro. Clin Exp Immunol 40: 168

    PubMed  Google Scholar 

  29. Wrann M, Bodmer S, Demartin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T cell suppressor factor from human glioblastoma cells is a 12.5 Kd protein closely related to transforming growth factor-beta. EMBO J 6: 1633

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Surgical Unit, St. Mary's Hospital, W2 1NY, Paddington, London, England UK

    Shaw S. Somers, Julian F. Dye & Pierre J. Guillou

Authors
  1. Shaw S. Somers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julian F. Dye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre J. Guillou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Somers, S.S., Dye, J.F. & Guillou, P.J. Comparison of transforming growth factor β and a human tumour-derived suppressor factor. Cancer Immunol Immunother 33, 217–222 (1991). https://doi.org/10.1007/BF01744940

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01744940

Key words

Search

Navigation